文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

Serelys Homme对接受激素治疗和放疗的局限性前列腺癌患者血管舒缩症状发生率与严重程度及生活质量损害的影响:ESCULAPE 2期前瞻性研究结果

Effect of Serelys Homme on the Incidence and Severity of Vasomotor Symptoms and Quality-of-Life Impairments in Patients Receiving Hormone Therapy and Radiation for Localized Prostate Cancer: Results of the ESCULAPE Phase 2 Prospective Study.
PubMed 文献 · Adv Radiat Oncol · 2023-04-24

ESCULAPE 2期前瞻性研究纳入46例接受雄激素剥夺治疗(ADT)联合放疗的局限性前列腺癌患者,每日服用Serelys Homme 2片共6个月。结果显示每日≥7次和3-6次血管舒缩症状(VMS)的患者比例显著下降,中重度VMS患者数在D90和D180减少(均P=0.005),VMS持续时间缩短,疲乏显著改善,全组无副作用记录。

要点

  • Serelys Homme每日2片共6个月,可显著减少ADT相关潮热盗汗的频率、持续时间与强度。
  • 中重度VMS患者比例在D90和D180均显著下降(P=0.005),疲乏等生活质量指标改善。
  • 全组46例患者未记录到副作用,医生评价VMS控制为中等者占20%、良好至优者占60%。

核心结论

  • 本研究显示Serelys Homme有效且耐受性极好,显著减少ADT所致潮热盗汗的频率、持续时间和强度,并提高生活质量评分。
  • 作者认为这些令人鼓舞的结果为进一步研究和在前列腺癌ADT患者中使用Serelys Homme开辟了前景。

研究设计与样本

  • ESCULAPE为2期前瞻性研究,2017年4月至2019年7月筛查103例,53例拒绝参与。
  • 50例患者纳入,4例退出,最终46例接受术后或根治性放疗联合短期(n=15)或长期(n=31)ADT。
  • 干预为Serelys Homme每日2片共6个月,于第0天、第90天(D90)和第180天(D180)用4份问卷评估。
  • 统计采用Wilcoxon符号秩检验,双侧P<.05为有统计学意义。

主要发现

  • Serelys Homme显著降低每日≥7次VMS和每日3-6次VMS的患者比例。
  • 中重度VMS患者数在D90(P=0.005)和D180(P=0.005)减少。
  • VMS持续时间在D90(P=0.002)和D180(P<.001)缩短。
  • 初始中重度VMS患者中,D90有11.1%、D180有16.0%达到完全缓解、无进一步症状。
  • 生活质量参数中疲乏显著下降;医生评价VMS控制为中等者占20%、良好至优者占60%;全组无副作用记录。

关键数值与推荐

  • Serelys Homme为每日2片、共6个月的方案。
  • 评估工具包括adapted-MRS、EQ 5D3L、FACT-P和HFRDIS,评估时间点为第0天、D90和D180。

临床怎么用

  • 原文结论未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Androgen deprivation therapy (ADT) may cause vasomotor symptoms (VMS) including hot flushes and sweats, which affect quality of life (QoL). Serelys Homme is a nonhormonal and a natural origin product that could affect VMS in men undergoing ADT. We evaluated effectiveness and tolerance of Serelys Homme administration on VMS and QoL of patients undergoing combined ADT and radiation therapy for prostate cancer. METHODS AND MATERIALS: Between April 2017 and July 2019, 103 patients were screened, and 53 patients refused to participate in the study. Serelys Homme therapy consisted of a daily administration of 2 tablets for 6 months. Patients were evaluated with 4 questionnaires including the adapted Modified Rankin Scale (adapted-MRS), European Quality of Life 5 Dimensions 3 Level Version (EQ 5D3L), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and Hot Flash Related Daily Interference Scale (HFRDIS) at day 0, day 90 (D90), and day 180 (D180). Statistical evaluation was performed using the Wilcoxon rank sign test. A 2-sided P < .05 was considered statistically significant. RESULTS: Among the 50 patients, 4 withdrew after inclusion. All patients (n = 46) received either postoperative or definitive radiation therapy combined with a short (n = 15) or long course (n = 31) of ADT. Serelys Homme administration significantly decreased the rate of patients who had ≥7 VMS and 3 to 6 VMS per day. The number of patients presenting with moderate or severe VMS was decreased at D90 (P = .005) and at D180 (P = .005). In addition, VMS duration was reduced at D90 (P = .002) and D180 (P < .001). Finally, at D90 and D180, 11.1% and 16.0% of patients, respectively, with initial severe or moderate VMS had a complete response without further symptoms. Among QoL parameters, fatigue decreased significantly. Effectiveness evaluated by doctors was rated as moderate or good to excellent VMS control in 20% and 60% of the patients, respectively. No side effects were recorded in the whole population. CONCLUSIONS: This study demonstrated effectiveness and excellent tolerance of Serelys Homme. We observed a significant reduction of the frequency, duration, and intensity of hot flushes and sweats induced by ADT. Serelys Homme increased QoL scores. These encouraging results open the prospect to further studies and Serelys Homme use in patients undergoing ADT for prostate cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Belkacemi Y, Coraggio G, Brunel A, et al. Effect of Serelys Homme on the Incidence and Severity of Vasomotor Symptoms and Quality-of-Life Impairments in Patients Receiving Hormone Therapy and Radiation for Localized Prostate Cancer: Results of the ESCULAPE Phase 2 Prospective Study. Adv Radiat Oncol. 2023. PMID: 37408674. doi:10.1016/j.adro.2023.101255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。